Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33

1.

Elongation factor-2 kinase regulates TG2/β1 integrin/Src/uPAR pathway and epithelial-mesenchymal transition mediating pancreatic cancer cells invasion.

Ashour AA, Gurbuz N, Alpay SN, Abdel-Aziz AA, Mansour AM, Huo L, Ozpolat B.

J Cell Mol Med. 2014 Nov;18(11):2235-51. doi: 10.1111/jcmm.12361.

2.

Down-regulation of 5-HT1B and 5-HT1D receptors inhibits proliferation, clonogenicity and invasion of human pancreatic cancer cells.

Gurbuz N, Ashour AA, Alpay SN, Ozpolat B.

PLoS One. 2014 Aug 29;9(8):e105245. doi: 10.1371/journal.pone.0105245.

3.

Tumour microenvironments induce expression of urokinase plasminogen activator receptor (uPAR) and concomitant activation of gelatinolytic enzymes.

Magnussen S, Hadler-Olsen E, Latysheva N, Pirila E, Steigen SE, Hanes R, Salo T, Winberg JO, Uhlin-Hansen L, Svineng G.

PLoS One. 2014 Aug 26;9(8):e105929. doi: 10.1371/journal.pone.0105929.

4.

MiR-221/-222 differentiate prognostic groups in advanced breast cancers and influence cell invasion.

Falkenberg N, Anastasov N, Rappl K, Braselmann H, Auer G, Walch A, Huber M, Höfig I, Schmitt M, Höfler H, Atkinson MJ, Aubele M.

Br J Cancer. 2013 Nov 12;109(10):2714-23. doi: 10.1038/bjc.2013.625.

5.

A cleavage-resistant urokinase plasminogen activator receptor exhibits dysregulated cell-surface clearance.

Nieves EC, Manchanda N.

J Biol Chem. 2010 Apr 23;285(17):12595-603. doi: 10.1074/jbc.M109.008581.

6.

The urokinase receptor promotes cancer metastasis independently of urokinase-type plasminogen activator in mice.

Jo M, Takimoto S, Montel V, Gonias SL.

Am J Pathol. 2009 Jul;175(1):190-200. doi: 10.2353/ajpath.2009.081053.

7.

Urokinase receptor mediates lung fibroblast attachment and migration toward provisional matrix proteins through interaction with multiple integrins.

Zhu S, Gladson CL, White KE, Ding Q, Stewart J Jr, Jin TH, Chapman HA Jr, Olman MA.

Am J Physiol Lung Cell Mol Physiol. 2009 Jul;297(1):L97-108. doi: 10.1152/ajplung.90283.2008.

8.

Structural basis of interaction between urokinase-type plasminogen activator and its receptor.

Barinka C, Parry G, Callahan J, Shaw DE, Kuo A, Bdeir K, Cines DB, Mazar A, Lubkowski J.

J Mol Biol. 2006 Oct 20;363(2):482-95.

9.

Urokinase-type plasminogen activator modulates airway eosinophil adhesion in asthma.

Brooks AM, Bates ME, Vrtis RF, Jarjour NN, Bertics PJ, Sedgwick JB.

Am J Respir Cell Mol Biol. 2006 Oct;35(4):503-11.

10.

Urokinase-catalysed cleavage of the urokinase receptor requires an intact glycolipid anchor.

Høyer-Hansen G, Pessara U, Holm A, Pass J, Weidle U, Danø K, Behrendt N.

Biochem J. 2001 Sep 15;358(Pt 3):673-9.

11.

Soluble urokinase receptor released from human carcinoma cells: a plasma parameter for xenograft tumour studies.

Holst-Hansen C, Hamers MJ, Johannessen BE, Brünner N, Stephens RW.

Br J Cancer. 1999 Sep;81(2):203-11.

12.

Comparison of immunohistochemistry with immunoassay (ELISA) for the detection of components of the plasminogen activation system in human tumour tissue.

Ferrier CM, de Witte HH, Straatman H, van Tienoven DH, van Geloof WL, Rietveld FJ, Sweep CG, Ruiter DJ, van Muijen GN.

Br J Cancer. 1999 Mar;79(9-10):1534-41.

13.

Urokinase type plasminogen activator receptor expression in colorectal neoplasms.

Suzuki S, Hayashi Y, Wang Y, Nakamura T, Morita Y, Kawasaki K, Ohta K, Aoyama N, Kim SR, Itoh H, Kuroda Y, Doe WF.

Gut. 1998 Dec;43(6):798-805.

14.

Urokinase receptor (CD87) regulates leukocyte recruitment via beta 2 integrins in vivo.

May AE, Kanse SM, Lund LR, Gisler RH, Imhof BA, Preissner KT.

J Exp Med. 1998 Sep 21;188(6):1029-37.

16.

Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants.

Mazzieri R, Masiero L, Zanetta L, Monea S, Onisto M, Garbisa S, Mignatti P.

EMBO J. 1997 May 1;16(9):2319-32.

17.

Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue.

Luther T, Magdolen V, Albrecht S, Kasper M, Riemer C, Kessler H, Graeff H, Müller M, Schmitt M.

Am J Pathol. 1997 Apr;150(4):1231-44.

18.

Maspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells.

Sheng S, Carey J, Seftor EA, Dias L, Hendrix MJ, Sager R.

Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11669-74.

20.

alpha-2 Macroglobulin receptor/Ldl receptor-related protein(Lrp)-dependent internalization of the urokinase receptor.

Conese M, Nykjaer A, Petersen CM, Cremona O, Pardi R, Andreasen PA, Gliemann J, Christensen EI, Blasi F.

J Cell Biol. 1995 Dec;131(6 Pt 1):1609-22.

Items per page

Supplemental Content

Support Center